KURA FY 2024 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M

Gross Profit

$54M100.0% margin

Operating Income

-$193M-358.5% margin

Net Income

-$174M-322.9% margin

EPS (Diluted)

$-2.02

Cash Flow

Operating Cash Flow

$134M

Free Cash Flow

$134M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$760M

Total Liabilities

$347M

Stockholders' Equity

$414M

Cash & Equivalents

$224M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$0	—
Gross Profit	$54M	-$849,000	+6446.6%
Operating Income	-$193M	-$166M	-16.5%
Net Income	-$174M	-$153M	-14.0%